Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

Title:Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

Volume: 19 Issue: 29

Author(s): Luca Miele, Giuseppe Marrone, Cristiano Lauritano, Consuelo Cefalo, Antonio Gasbarrini, Chris Day and Antonio Grieco

Affiliation:

Keywords: Gut-liver axis, intestinal permeability, insulin resistance, human microbiota, NAFLD, portal hypertension.

Abstract: There is increasing evidence for a correlation between intestinal microbiota, bacterial translocation and hepatic steatosis. Intestinal microbiota affects nutrient absorption and energy homeostasis. Altered intestinal permeability may favor the passage of bacteriaderived compounds into systemic circulation, causing a systemic inflammatory state, characteristic of the metabolic syndrome. The interaction between intestinal permeability and luminal bacteria is involved in the pathogenesis and evolution of non-alcoholic liver disease. Microbiota pharmacological modulation could be a promising tool for a new therapeutical approach to non-alcoholic fatty liver disease.

Cite this article as:

Miele Luca, Marrone Giuseppe, Lauritano Cristiano, Cefalo Consuelo, Gasbarrini Antonio, Day Chris and Grieco Antonio, Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290011